Targeted delivery of Botulinum toxin for the treatment and prevention of trigeminal autonomic cephalgias, migraine and vascular conditions

Details for Australian Patent Application No. 2012241076 (hide)

Owner Allergan, Inc.

Inventors Blumenfeld, Andrew M.

Agent Davies Collison Cave

Pub. Number AU-A-2012241076

Parent 2005326660

Filing date 12 October 2012

Wipo publication date 1 November 2012

International Classifications

A61K 38/16 Medicinal preparations containing peptides - Peptides having more than 20 amino acids

A61K 35/74 Medicinal preparations containing material or reaction products thereof with undetermined constitution

Event Publications

25 October 2012 Complete Application Filed

1 November 2012 Application Open to Public Inspection

  Published as AU-A-2012241076

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012241077-Inhibitors of IAP

2012241075-Flexible circuit electrode array with at least one tack opening